Noxopharm is a Group comprising Noxopharm Ltd, Nyrada Inc, and NoxAsia Ltd with offices in Sydney, New York and Hong Kong. The Group's drug pipeline contains 4 drug candidates: Veyonda®, NYX-104, NYX-205, NYX-330. Veyonda® is being developed as an enhancer of radiotherapy across a range of cancers, including prostate cancer patients being treated with both standard external beam radiotherapy and intravenous radionuclide (177lutetium-PSMA-617) therapy; NYX-104 is a neuroprotectant being developed to limit secondary brain damage (glutamate-induced excitotoxicity) following ischaemic stroke and concussion; NYX-205 is an anti-inflammatory being developed for the treatment of peripheral neuropathy associated with diabetes and chemotherapy; NYX-330 is a PCSK9 inhibitor being developed for the treatment of high blood LDL cholesterol levels that fail to respond adequately to statin therapy alone.

Veyonda® is the first pipeline product, previously known as NOX66. It is currently in clinical trials. It has also been trialled as an enhancer of chemotherapy across a range of cancers.

Latest Media Releases

Noxopharm Corporate Presentation June 2019

06/06/2019 09:59:00

SYDNEY, June 6, 2019: Noxopharm Ltd (ASX: NOX) (Noxopharm or ‘Company’) is pleased to provide the market with its updated corporate presentation for June 2019. For further inf…

Noxopharm’s DARRT-1 Study Fully Enrolled

30/05/2019 09:04:00

Final patient enrolled into study Topline data to be announced in Q4 2019 SYDNEY, 30 May 2019: Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to…

Latest News